Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of IV Ampion in COVID-19 Patients Requiring Oxygen
NCT04456452Phase 1Completed
- Sponsor
- Ampio Pharmaceuticals, Inc.
- Start
- Jul 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Ampion + SoC with Standard of Care (2 arms). Primary endpoint: Incidence and severity of adverse events at Day 5. Started Jul 2020; status: completed.
02
Drugs
aspartyl-alanyl-diketopiperazine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04456452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04456452.